Home LiteratureArticle Details
PMID: 12724482 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

The New England journal of medicine ·Vol. 348 ·No. 18 ·2003-05-01 ·Pages 1764-75

Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marcé S, López-Guillermo A, Campo E, Montserrat E

Abstract

The mutational status of immunoglobulin heavy-chain variable-region (IgVH) genes in the leukemic cells of chronic lymphocytic leukemia (CLL) is an important prognostic factor in the disease. We investigated whether the expression of ZAP-70 by CLL cells correlated with the IgVH mutational status, disease progression, and survival. The expression of ZAP-70 was analyzed in T-cell and B-cell lines and in peripheral-blood samples from 56 patients with CLL with the use of flow cytometry, Western blotting, and immunohistochemistry. The results were correlated with the IgVH mutational status and clinical outcome. ZAP-70 was detected by flow-cytometric analysis in cells of T-cell lineage and in leukemic cells from 32 of 56 patients with CLL. In all patients in whom at least 20 percent of the leukemic cells were positive for ZAP-70, IgVH was unmutated, whereas IgVH mutations were found in 21 of 24 patients in whom less than 20 percent of the leukemic cells were positive for ZAP-70 (P<0.001). Concordant results were obtained when ZAP-70 expression was assessed by immunohistochemistry or Western blotting. The level of ZAP-70 expression did not change over time (median, 37 months) in sequential samples from 30 patients with CLL. Patients with Binet stage A CLL who had at least 20 percent ZAP-70-positive leukemic cells had more rapid progression and poorer survival than those with less than 20 percent ZAP-70-positive cells. Among patients with CLL, expression of ZAP-70, as detected by flow-cytometric analysis, correlated with IgVH mutational status, disease progression, and survival.

MeSH Terms
ADP-ribosyl Cyclase/analysis ADP-ribosyl Cyclase 1 Antigens, CD/analysis Disease Progression Flow Cytometry Genes, Immunoglobulin Humans Immunoglobulin Heavy Chains/genetics Immunoglobulin Variable Region/genetics Leukemia, Lymphocytic, Chronic, B-Cell/genetics,immunology,mortality Membrane Glycoproteins Mutation Prognosis Protein-Tyrosine Kinases/genetics,metabolism Receptors, Antigen, T-Cell/genetics,metabolism Survival Analysis ZAP-70 Protein-Tyrosine Kinase
Chemicals
Antigens, CD Immunoglobulin Heavy Chains Immunoglobulin Variable Region Membrane Glycoproteins Receptors, Antigen, T-Cell Protein-Tyrosine Kinases ZAP-70 Protein-Tyrosine Kinase ZAP70 protein, human ADP-ribosyl Cyclase CD38 protein, human ADP-ribosyl Cyclase 1
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Crespo Marta
Department of Hematology, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Barcelona, Spain.
Bosch Francesc
Villamor Neus
Bellosillo Beatriz
Colomer Dolors
Rozman María
Marcé Silvia
López-Guillermo Armando
Campo Elies
Montserrat Emili
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
1533-4406
Published
2003-05-01
Pages
1764-75
Language
English
Region
United States
NLM ID
0255562
Subset
IM
Corrections
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com